Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2020)
12 slides from Idt Australia's shareholder meeting presentation, Nov 17, 2020
Slide 1: IDT Australia Limited 2020 Annual General Meeting
For personal use only IDT AUSTRALIA LIMITED 2020 ANNUAL GENERAL MEETING 17 November 2020
Slide 2: Key Operational Highlights
Key Operational Highlights For personal use only IDT remained operational throughout the COVID-19 crisis and has assisted with the Australian Government’s initial COVID-19 response efforts A positive EBITDA was achieved for FY20, representing a year on year improvement of 122%* Top-line revenu
Slide 3: FY20 Financial Highlights
FY`20 Financial Highlights Strong progress towards profitability For personal use only Year-on-year Revenue growth of 17% to $14.2 million Year ended 30 June (‘$000) 2020 2019 Variance (which includes $0.9 million previously capitalised milestone) Revenue 14,169 12,130 2,039 17% Positive EBITDA
Slide 4: Year In Review
Year In Review* Execute Medicinal Cannabis For personal use only Manufacturing Plan Drive and Grow The Business Developed medicinal cannabis solvent YoY Revenue up 17% to $14.2m extraction and Oil-In-Bottle products Capital Management and Cost Medicinal Cannabis Containment Supply and Distribu
Slide 5: Medicinal Cannabis Manufacturing Plan
Medicinal Cannabis Manufacturing Plan For personal use only IDT continues to execute on its Medicinal Cannabis Manufacturing Plan Commercial scale cGMP solvent extraction of medicinal cannabis resin is now in routine batch manufacture cGMP medicinal cannabis Oil-In-Bottle products are being co
Slide 6: COVID-19 Pandemic Response
COVID-19 Pandemic Response For personal use only Throughout the COVID-19 crisis IDT’s cGMP pharmaceutical manufacturing facilities and laboratories remained fully operational and the Company’s business operations have continued with minimal disruption IDT implemented internal management of COVID
Slide 7: Sovereign Manufacturing – Australia's Pharmaceutical Supply Chain
Sovereign Manufacturing – Australia’s Pharmaceutical Supply Chain For personal use only Disruption to global pharmaceutical supply chains brought on by the COVID-19 crisis highlighted the fundamental sovereign risk associated with outsourcing Australia’s drug manufacturing to other countries. Pres
Slide 8: Year Ahead
Year Ahead For personal use only COVID-19 Treatment and Vaccine Manufacture – TGA and Advance IDT’s Sovereign FDA accredited site at the ready Manufacturing Initiative Pushing Towards A Return To Continue To Execute IDT’s Operational Profitability Medicinal Cannabis Manufacturing Plan Finalise Devel
Slide 9: Corporate Snapshot
IDT Australia Limited Corporate Snapshot For personal use only -------------------------------------------------------------------------------------------- 23 cents Shares on issue 238,324,664 Options Nil Market Cap (as at 12 Nov 20) $46.5m Top 20 holders 67% of IC Year high 23 cents Year low 8 cent
Slide 10: Board of Directors and Executive Team
IDT Australia Limited For personal use only Board of Directors Executive Team Mr Alan Fisher Chair Dr David Sparling CEO Finance specialist with key experience in business restructuring More than 20 years of pharma and diagnostics experience in and company turnarounds CEO, Director and Corporate/Bus
Slide 11: Q&A
Q&A Ajuo esn feuosied 10} ict
Slide 12: Proxy Voting Summary
Proxy Voting Summary For personal use only Resolution Lodged For Lodged Open Lodged Against Total Available Votes %IC Votes Holders % Votes Holders % Votes Holders % 1 Adoption of Remuneration Report 73,795,904 55 94.68% 201,764 7 0.26% 3,948,608 27 5.07% 77,946,276 32.71% 2 Election of Michael Kots